Ablynx continues to rise
After the takeover bid on Ablynx, its share is picking up again and leaves the offer price of Novo Nordisk behind. Ablynx became the strongest climber on the market (+10,5%). Full article here.
The biotech company now assumes a market potential of €1.2 billion for caplacizumab, its drug against the rare blood disease TTP, instead of €800 million before. Full article in De Tijd.